All patients | Group 1 BCLC-B too large for TACE alone | Group 2 BCLC-B progression post TACE | Group 3 BCLC-C sorafenib eligible | Group 4 BCLC-C sorafenib unsuitable | |
Patient number | 51 | 21 | 7 | 16 | 7 |
age—median (range) | 72 (39–84) | 72 (51–84) | 76 (62–81) | 68 (50–81) | 72 (39–84) |
Sex M/F | 41/10 | 15/6 | 6/1 | 16/0 | 4/3 |
Aetiology—no CLD | 8 | 3 | 0 | 2 | 3 |
ARLD | 9 | 3 | 3 | 3 | 0 |
NAFLD | 19 | 10 | 2 | 5 | 2 |
HCV | 9 | 3 | 0 | 5 | 1 |
Other | 6 | 2 | 2 | 1 | 1 |
Cirrhosis N/Y | 20/31 | 11/10 | 1/6 | 5/11 | 3/4 |
Child-Pugh A | 51 | 21 | 7 | 16 | 7 |
ECOG PST 0/1/2 | 21/22/8 | 14/7/0 | 3/4/0 | 4/8/4 | 0/3/4 |
Tumour number 1/>1 | 30/21 | 14/7 | 2/5 | 10/6 | 4/3 |
Size—median, cm (range) | 8.5 (3.3–19.1) | 9.7 (5.3–19.1) | 5.9 (3.3–11.0) | 8.8 (3.7–13.0) | 8.3 (3.8–17.0) |
Total activity—median GBq (range) | 3.2 (1.04–10.77) | 3.93 (1.49–10.77) | 2.32 (1.04–3.20) | 3.20 (1.61–6.67) | 2.8 (1.26–6.53) |
Branch PVT N/Y | 39/12 | 21/0 | 7/0 | 6/10 | 5/2 |
Unilobar Y/N | 39/12 | 16/5 | 5/2 | 13/3 | 5/2 |
Prior therapy Y/N | 17/34 | 2/19 | 7/0 | 5/11 | 3/4 |
Next therapies | |||||
Resection | 5 | 5 | 0 | 0 | 0 |
Active monitoring | 3 | 3 | 0 | 0 | 0 |
Further SIRT | 1 | 0 | 0 | 1 | 0 |
Medical 1 L | 8 | 1 | 2 | 5 | 0 |
Medical 1l+2 L | 7 | 3 | 0 | 3 | 1 |
Supportive care | 27 | 9 | 5 | 7 | 6 |
mRECIST PR/SD/PD (3 months) | 25/11/14 | 12/6/2 | 2/0/5 | 7/5/4 | 4/0/3 |
Median survival (months) | |||||
All—median | 20.17 | Ongoing | 14.8 | 20.2 | 4.2 |
Resection n=5 | Ongoing | All alive | – | – | – |
Non-resected | 15.5 | 21.7 | – | – | – |
First-line SIRT | 21.67 | Ongoing | – | 27.4 | 3.7 |
Second-line SIRT | 10.93 | 42.1 | 14.8 | 10.7 | 7.3 |
Unilobar | 19.87 | Ongoing | 11.4 | 27.4 | 4.2 |
Bilobar | 10.93 | 20.2 | 14.8 | 8.8 | 3.2 |
+PVT | 10.7 | – | – | 10.7 | 2.7 |
ARLD, alcohol related liver disease; BCLC, Barcelona clinic liver cancer; CLD, chronic liver disease; ECOG PST, European Co-operative Oncology Group Performance Status; F, female; GBq, gigabecquerel; HCV, hepatitis C virus; 1L, first line; 2L, second line; M, male; mRECIST, modified response evaluation criteria in solid tumours; N, no; NAFLD, non-alcoholic fatty liver disease; PVT, portal vein thrombus; SIRT, selective internal radiation therapy; TACE, transarterial chemoembolisation; Y, yes.